Skip to main
ARCT
ARCT logo

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics (ARCT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Arcturus Therapeutics Holdings Inc. is positioned favorably within the RNA medicines sector, with promising advancements in its pipeline targeting liver and respiratory diseases. Recent preliminary data indicates a noteworthy improvement in forced expiratory volume (FEV1) among treated patients, with a reported average absolute increase of 3.8% and a relative increase of 5.1% from baseline to Day 42, despite acknowledging the need for cautious interpretation of these exploratory results. Additionally, the company's innovative approach, including the newly developed assay for measuring urea cycle function, along with its ongoing efforts in intellectual property defense, underscore the potential for enhanced commercial viability and value creation in the future.

Bears say

Arcturus Therapeutics Holdings Inc. faces a negative outlook primarily due to disappointing interim data from its ARCT-032 Phase 2 trial, which failed to demonstrate a meaningful improvement in FEV1, leading to the removal of this asset from the company's valuation model. Additionally, the potential for delays in clinical trials or unexpected safety and efficacy issues for several key pipeline products increases downside risk and contributes to a lower market confidence in the company's future prospects. Furthermore, Arcturus's inability to defend its patents raises the threat of increased competition from generic alternatives, further complicating its position in the market.

Arcturus Therapeutics (ARCT) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcturus Therapeutics (ARCT) Forecast

Analysts have given Arcturus Therapeutics (ARCT) a Buy based on their latest research and market trends.

According to 7 analysts, Arcturus Therapeutics (ARCT) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcturus Therapeutics (ARCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.